Turk Ilac ve SerumnayiIST:TRILC +0.84%61 PS Ratio is 0.43 as of Jul. 08, 2026, which is 67% below its 10-year median of 1.32. GuruFocus rates IST:TRILC with a GF Score™ of 61/100 and a GF Value™ of ₺3.61 (Possible Value Trap). The stock has 11 warning signs investors should review. Among 952 Drug Manufacturers companies, Turk Ilac ve Serumnayi ranks better than 90.34% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Turk Ilac ve Serumnayi's share price is ₺1.20.
Turk Ilac ve Serumnayi's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2025 was ₺2.76. Hence, Turk Ilac ve Serumnayi's PS Ratio for today is 0.43.
Good Sign:
Turk Ilac ve Serum Sanayi stock PS Ratio (=0.42) is close to 10-year low of 0.42.
The historical rank and industry rank for Turk Ilac ve Serumnayi's PS Ratio or its related term are showing as below:
IST:TRILC'
s PS Ratio Range Over the Past 10 Years
Min: 0.42 Med: 1.32 Max: 25.95
Current: 0.43
During the past 5 years, Turk Ilac ve Serumnayi's highest PS Ratio was 25.95. The lowest was 0.42. And the median was 1.32.
IST:TRILC's PS Ratio is ranked better than 90.34% of 952
companies
in the Drug Manufacturers industry
Industry Median: 2.29
vs IST:TRILC: 0.43
During the past 5 years, Turk Ilac ve Serumnayi's highest 3-Year average Revenue per Share Growth Rate was 140.60% per year. The lowest was 56.30% per year. And the median was 98.45% per year.
Back to Basics: PS Ratio
Turk Ilac ve Serumnayi (IST:TRILC) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Turk Ilac ve Serumnayi's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Turk Ilac ve Serumnayi PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Turk Ilac ve Serumnayi's PS Ratio distribution charts can be found below:
* The bar in red indicates where Turk Ilac ve Serumnayi's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Turk Ilac ve Serumnayi's Share Price of today is ₺1.20. Turk Ilac ve Serumnayi's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₺2.76.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Turk Ilac ve Serumnayi (IST:TRILC) has a PS Ratio of 0.43 as of Jul. 08, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Turk Ilac ve Serumnayi and its competitors. This is 67% below median its historical median of 1.32. Over the past decade, Turk Ilac ve Serumnayi's PS Ratio has ranged from 0.42 to 25.95. According to the industry distribution chart, Turk Ilac ve Serumnayi ranks #92 out of 952 companies in the Drug Manufacturers industry, placing it in the top 9.7%.
Is Turk Ilac ve Serumnayi's PS Ratio too high?
Turk Ilac ve Serumnayi's current PS Ratio of 0.43 is 67% below median its 10-year median of 1.32. Over the past 10 years, this metric has ranged from a low of 0.42 to a high of 25.95. The Drug Manufacturers industry median PS Ratio is 2.29. Turk Ilac ve Serumnayi's value of 0.43 is 81.2% below this industry median. Based on the distribution chart, Turk Ilac ve Serumnayi ranks #92 out of 952 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Turk Ilac ve Serumnayi has a GF Score™ of 61/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Turk Ilac ve Serumnayi's PS Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Turk Ilac ve Serumnayi ranks #92 out of 952 companies for PS Ratio. This places Turk Ilac ve Serumnayi in the top 10% of its industry — outperforming the majority of peers. The industry median PS Ratio is 2.29. Turk Ilac ve Serumnayi's value of 0.43 is 81.2% below this benchmark. Historically, Turk Ilac ve Serumnayi's own PS Ratio has ranged from 0.42 to 25.95 over the past decade. While the company's 10-year median is 1.32 vs. the industry median of 2.29, Turk Ilac ve Serumnayi has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.29, based on 952 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Turk Ilac ve Serumnayi's current PS Ratio of 0.43 is 81.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Turk Ilac ve Serumnayi and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Turk Ilac ve Serumnayi's current PS Ratio is 0.43, which is 67% below median its own 10-year median of 1.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Turk Ilac ve Serumnayi stock overvalued right now?
Based on GuruFocus' analysis, Turk Ilac ve Serumnayi (IST:TRILC) is currently considered Possible Value Trap. The stock's GF Value™ is ₺3.61, compared to a current price of ₺1.20 — trading 66.8% below its estimated fair value. The current PS Ratio is 0.43, which is 67% below median its 10-year median of 1.32 and 81.2% below the Drug Manufacturers industry median of 2.29. Turk Ilac ve Serumnayi's overall GF Score™ is 61/100 with 11 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Turk Ilac ve Serumnayi (IST:TRILC), the current PS Ratio is 0.43 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Turk Ilac ve Serumnayi (IST:TRILC) Overvalued in 2026?
Based on GuruFocus' analysis, Turk Ilac ve Serumnayi stock appears to be undervalued.
The current stock price of ₺1.20 is trading 66.8% below its estimated GF Value™ of ₺3.61.
GuruFocus considers Turk Ilac ve Serumnayi to be Possible Value Trap.
Key valuation signals for IST:TRILC:
PS Ratio: 0.43 (67% below median its 10-year median of 1.32)
GF Value™: ₺3.61 vs. price of ₺1.20 (66.8% below fair value)
Industry Position: 81.2% below the Drug Manufacturers median (#92 of 952)
No single metric tells the full story. See the IST:TRILC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IST:TRILC has been successfully added to your 
